The Thing That Makes Regain Inevitable

When you lose weight, your body burns less energy than its new size predicts, and it keeps doing so. That gap — metabolic adaptation — is the leading explanation for why weight loss plateaus and why it comes back. A study asked whether tirzepatide interrupts it. In mice it did. In people it did not.^[1]

What metabolic adaptation is

A smaller body needs less fuel, and everyone expects energy expenditure to fall as weight comes off. Metabolic adaptation is the part that falls further than that — a reduction beyond what the change in body size accounts for, which persists rather than resolving.

It is why maintaining a reduced weight is harder than reaching it, and it is a large part of why the same eating that produced weight loss stops producing it. Any drug that switched it off would be doing something genuinely new.

The mouse result and the human result

The mouse arm is a careful design. Comparing against pair-fed animals — ones fed the same reduced amount without the drug — separates the effect of eating less from the effect of the drug. On that comparison, tirzepatide blunted the fall in energy expenditure.

The mechanism worked in mice and did not appear in people. The paper's title reports the human result.

That title choice is worth crediting. A study with a positive animal finding and a null human one could easily have led with the mouse. This one did not.

This is the second time

That pattern is worth holding onto whenever a mechanism story appears. Mice are where mechanisms get established, because you can do things to a mouse you cannot do to a person. They are also where mechanisms most often stop.

What did carry over

Two effects appeared in both species. Fat oxidation increased — the body shifted toward burning fat rather than carbohydrate, without total expenditure changing. And in people, appetite and calorie intake fell at a laboratory meal with unlimited access.

That second measurement is the one we covered separately from the same research program, where participants ate 524.6 fewer calories at a single weighed lunch without any increase in deliberate restraint — five hundred calories at one lunch.

Together those give a coherent account of how the drug works, and it is a narrower one than people assume: it changes what you eat and what you burn it as, not how much energy you spend.

What follows, and what does not

Within that limit, the practical implication is unwelcome and worth knowing. If metabolic adaptation is untouched, then the physiological pressure that makes maintenance hard is still there while someone is on the drug, and it is waiting when they come off. That is consistent with what the withdrawal trials show — what happens when you stop — and with regain being biology rather than a failure of resolve.

It also fits the shape of the plateau. Weight loss slowing after six to eight months is what a curve does when the drug reduces intake while the body’s defense of its weight continues uninterrupted — the timings are in what a plateau actually means.

The authors are employees of the company that makes tirzepatide, which is ordinary for a mechanistic phase 1 program and worth noting in a study reporting a null result about their own drug.